Journals / Nöropsikiyatri Arşivi / 2022 / Cilt: 59 - Sayı: 1

Determinants of Disability in Progressive Onset Multiple Sclerosis

Progresif Başlangıçlı Multipl Skleroz’da Özürlülük Belirleyicileri

Pages
10–13
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to confirm and validate these findings and to provide greater insight into the effects of ethnic or geographical differences on the course.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To describe the clinical and socio-demographic profiles of the patients with the progressive onset Multiple Sclerosis (MS) and to explore the determinants of disability.
📊
Key Findings & Data:Method: This is a retrospective study, which was conducted in a university hospital.
💡
Conclusion & Impact:Further studies are needed to confirm and validate these findings and to provide greater insight into the effects of ethnic or geographical differences on the course.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: To describe the clinical and socio-demographic profiles of the patients with the progressive onset Multiple Sclerosis (MS) and to explore the determinants of disability. Method: This is a retrospective study, which was conducted in a university hospital. Patients with a progressive clinical course at onset were included in the study. In the first analysis, the clinical and demographic properties of the cohort were defined. In the second analysis the effects of age, sex, clinical activity during course, initial clinical symptoms and cerebrospinal fluid analyses on the course were evaluated. Results: Clinical activity during the course, older age, male gender, medulla spinalis involvement at onset and detection of paraparesis at initial neurological examination was found as a poor prognostic factor. Conclusion: This research confirms previous findings of the studies conducted in populations of Europe or America. Further studies are needed to confirm and validate these findings and to provide greater insight into the effects of ethnic or geographical differences on the course.

Özet

Amaç: Progresif başlangıçlı Multipl Sklerozlu (MS) hastaların klinik ve sosyo-demografik profillerini tanımlamak ve özürlülüğün belirleyicilerini araştırmak. Yöntem: Bu çalışma bir üniversite hastanesinde yürütülen retrospektif bir çalışmadır. Çalışmaya başlangıçta progresif klinik seyri olan MS hastaları dahil edildi. İlk analizde, kohortun klinik ve demografik özellikleri tanımlandı. İkinci analizde yaş, cinsiyet, seyir sırasındaki klinik aktivite, başlangıçtaki klinik semptomlar ve beyin omurilik sıvısı analizlerinin seyir üzerindeki etkileri değerlendirildi. Bulgular: Seyir sırasındaki klinik aktivite, ileri yaş, erkek cinsiyet, başlangıçta medulla spinalis tutulumu ve ilk nörolojik muayenede paraparezin saptanması kötü prognostik faktör olarak bulundu. Sonuç: Bu araştırma, Avrupa veya Amerika toplumlarında yapılan çalışmaların bulgularını doğrulamaktadır. Bu bulguların tekrarlanması ve etnik veya coğrafi farklılıkların hastalık üzerindeki etkilerini daha iyi anlaşılması için daha fazla çalışmaya ihtiyaç vardır.

🔖

Cite This Article

TÜTÜNCÜ, M., SAİP, S., SİVA, A., TÜTÜNCÜ, M. (2022). Determinants of Disability in Progressive Onset Multiple Sclerosis. Nöropsikiyatri Arşivi, Cilt: 59 - Sayı: 1, 10–13. https://ajindex.com/articles/584578

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kantarci OH. Phases and phenotypes of multiple sclerosis. Contin Lifelong Learn Neurol. 2019
  2. 25(3):636-654. [Crossref] 2. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G ve ark. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162–173. [Crossref] 3. Montalban X, J. Sastre-Garriga, M. Filippi, Z. Khaleeli, N. Téllez, M. Vellinga ve ark. “Primary progressive multiple sclerosis diagnostic criteria: A reappraisal,” Multiple Sclerosis, 2009,15 (12) 1459-1465. [Crossref] 4. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000. Nov 16
  3. 343(20):1430- 14388. [Crossref] 5. Faissner S, Gold R. Progressive multiple sclerosis: latest therapeutic developments and future directions. Ther Adv Neurol Disord. 2019
  4. [Crossref] 6. Kaymakamzade B, Kiliç AK, Tuncer Kurne A, Karabudak R. Progressive Onset Multiple Sclerosis: Demographic, clinical and laboratory characteristics of patients with and without relapses in the course. Noropsikiyatri Ars. 2019
  5. 56(1):23-26. [Crossref] 7. Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017. Apr 1
  6. 389(10076):1357-1366 [Crossref] 8. Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ ve ark. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler J. 2013. Feb
  7. 19(2):188-198 [Crossref] 9. Ferreira Vasconcelos CC, Santos Thuler LC, Cruz dos Santos GA, Papais Alvarenga M, Papais Alvarenga M, Gomes Camargo SM ve ark. Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients. Mult Scler. 2010 May
  8. 16(5):597-603. [Crossref] 10. Vukusic S, Confavreux C. The natural history of multiple sclerosis. Handb Mult Sclerosis, Third Ed. 2001:433-447. [Crossref] 11. Ebers GC. Natural history of primary progressive multiple sclerosis. Mult Scler. 2004. Jun
  9. 10 Suppl 1:S8-13 [Crossref] 12. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain. 2006. Mar
  10. 129(Pt 3):606-616 [Crossref] 13. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J ve ark. The natural history of multiple sclerosis: A geographically based study: 2 Predictive value of the early clinical course. Brain. 1989. Dec
  11. 112 ( Pt 6):1419- 1428 [Crossref] 14. Cot